Kath Watson

8.0k total citations · 2 hit papers
79 papers, 5.8k citations indexed

About

Kath Watson is a scholar working on Rheumatology, Immunology and Genetics. According to data from OpenAlex, Kath Watson has authored 79 papers receiving a total of 5.8k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Rheumatology, 20 papers in Immunology and 18 papers in Genetics. Recurrent topics in Kath Watson's work include Rheumatoid Arthritis Research and Therapies (60 papers), Systemic Lupus Erythematosus Research (26 papers) and Chronic Lymphocytic Leukemia Research (18 papers). Kath Watson is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (60 papers), Systemic Lupus Erythematosus Research (26 papers) and Chronic Lymphocytic Leukemia Research (18 papers). Kath Watson collaborates with scholars based in United Kingdom, Australia and Norway. Kath Watson's co-authors include Deborah Symmons, Kimme L Hyrich, Mark Lunt, William G Dixon, Alan J. Silman, James Galloway, Andrew Ustianowski, Louise Mercer, Darren M. Ashcroft and Gary J. Macfarlane and has published in prestigious journals such as The Lancet, PEDIATRICS and Pain.

In The Last Decade

Kath Watson

77 papers receiving 5.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)

2009 532 citations William G Dixon, Kimme L Hyrich et al. Annals of the Rheumatic Diseases profile →
Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly

2010 496 citations James Galloway, Kimme L Hyrich et al. Lara D. Veeken profile →

Peers

Countries citing papers authored by Kath Watson

Since Specialization

Citations

This map shows the geographic impact of Kath Watson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kath Watson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kath Watson more than expected).

Fields of papers citing papers by Kath Watson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kath Watson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kath Watson. The network helps show where Kath Watson may publish in the future.

Co-authorship network of co-authors of Kath Watson

This figure shows the co-authorship network connecting the top 25 collaborators of Kath Watson. A scholar is included among the top collaborators of Kath Watson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kath Watson. Kath Watson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	P144 Socioeconomic deprivation is associated with reduced response and lower treatment persistence with anti-TNF therapies in people with rheumatoid arthritis 2023 ·Lara D. Veeken ·Sizheng Steven Zhao, Lianne Kearsley‐Fleet, (unknown), Kath Watson, Ailsa Bosworth, James Galloway, Suzanne Verstappen, (unknown), Jennifer Humphreys, Anne Barton, Kimme L Hyrich	1
2	Evaluation of serious infections, including Mycobacterium tuberculosis, during treatment with biologic disease-modifying anti-rheumatic drugs: does line of therapy matter? 2023 ·Lara D. Veeken ·Kim Lauper, Lianne Kearsley‐Fleet, James Galloway, Kath Watson, (unknown), Kimme L Hyrich, Mark Lunt	4
3	Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA 2017 ·RMD Open ·Meghna Jani, William G Dixon, Lianne Kearsley‐Fleet, Ian N Bruce, Hector Chinoy, Anne Barton, Mark Lunt, Kath Watson, (unknown), Deborah Symmons, Kimme L Hyrich	26
4	228. BIOSIMILARS IN THE UNITED KINGDOM: FIRST REAL-WORLD DATA FROM THE BRITISH SOCIETY FOR RHEUMATOLOGY BIOLOGICS REGISTERS FOR RHEUMATOID ARTHRITIS 2017 ·Lara D. Veeken ·Diederik De Cock, Kath Watson, Kimme L Hyrich	3
5	The influence of behavioural and psychological factors on medication adherence over time in rheumatoid arthritis patients: a study in the biologics era 2015 ·Lara D. Veeken ·Catharine Morgan, John McBeth, Lis Cordingley, Kath Watson, Kimme L Hyrich, Deborah Symmons, Ian N Bruce	68
6	P2. Incidence and Severity of Myocardial Infarction in Subjects Receiving Anti-Tumour Necrosis Factor Drugs for Rheumatoid Arthritis: Results from Linking the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis and Myocardial Ischaemia National Audit Project 2014 ·Lara D. Veeken ·(unknown), Kimme L Hyrich, Mark Lunt, Louise Mercer, Chris P Gale, Kath Watson, William G Dixon, Deborah Symmons	4
7	The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register 2012 ·Annals of the Rheumatic Diseases ·Louise Mercer, Adèle C. Green, James Galloway, Rebecca Davies, Mark Lunt, William G Dixon, Kath Watson, Deborah Symmons, Kimme L Hyrich	95
8	Rituximab or a second anti–tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti–tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register 2012 ·Arthritis Care & Research ·Moetaza M. Soliman, Kimme L Hyrich, Mark Lunt, Kath Watson, Deborah Symmons, Darren M. Ashcroft, (unknown)	63
9	Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register 2010 ·Lara D. Veeken ·Suzanne Verstappen, Kath Watson, Mark Lunt, (unknown), Deborah Symmons, Kimme L Hyrich, (unknown)	70
10	Influence of anti–tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: Results from the British Society for rheumatology biologics register 2010 ·Arthritis Care & Research ·William G Dixon, Kath Watson, Mark Lunt, Louise Mercer, Kimme L Hyrich, Deborah Symmons, (unknown)	152
11	No evidence of association between anti–tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register 2010 ·Arthritis & Rheumatism ·Mark Lunt, Kath Watson, William G Dixon, Deborah Symmons, Kimme L Hyrich, (unknown)	68
12	Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008 2010 ·Lara D. Veeken ·Kimme L Hyrich, Kath Watson, Mark Lunt, Deborah Symmons, (unknown)	69
13	Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register 2009 ·Arthritis Research & Therapy ·Amr Saad, Darren M. Ashcroft, Kath Watson, Kimme L Hyrich, Peter Noyce, Deborah Symmons, (unknown)	166
14	Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register 2009 ·Lara D. Veeken ·(unknown), Tracey Farragher, Mark Lunt, Kath Watson, Deborah Symmons, Kimme L Hyrich, (unknown)	91
15	Serious infection following anti–tumor necrosis factor α therapy in patients with rheumatoid arthritis: Lessons from interpreting data from observational studies 2007 ·Arthritis & Rheumatism ·William G Dixon, Deborah Symmons, Mark Lunt, Kath Watson, Kimme L Hyrich, Alan J. Silman	219
16	Influence of anti-tnf therapy and previous malignancy on cancer incidence in patients with Rheumatoid Arthritis (RA): Results from the BSR biologics register (BSRBR) 2006 ·Lara D. Veeken ·Kath Watson, William G Dixon, Kimme L Hyrich, Mark Lunt, Deborah Symmons, A J Silman	11
17	Influence of anti-TNF therapy and previous malignancy on cancer incidence in patients with rheumatoid arthritis (RA): Results from the BSR biologics register 2006 ·Annals of the Rheumatic Diseases ·Kath Watson, William G Dixon, Kimme L Hyrich, Mark Lunt, Deborah Symmons, A J Silman	18
18	All cause mortality is not increased following the use of anti-TNF agents in patients with rheumatoid arthritis: Results from a nationwide prospective study 2005 ·Arthritis & Rheumatism ·Kath Watson, (unknown), William G Dixon, Deborah Symmons, A J Silman	1
19	Anti-TNF therapy and mortality in rheumatoid arthritis patients registered with the British Society for Rheumatology Biologics Register (BSRBR) 2005 ·Annals of the Rheumatic Diseases ·Kath Watson, Kimme L Hyrich, A J Silman, (unknown), (unknown)	12
20	Low back pain in schoolchildren: Ocurrence and characteristics 2003 ·Revista de la Sociedad Española del Dolor ·Kath Watson, A C Papageorgiou, Gregory T. Jones, Stewart J. Taylor, Deborah Symmons, A J Silman, Gary J. Macfarlane	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact